{"filings":[{"id":918037,"accession_number":"0001339970-26-000039","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2026-06-08T20:04:31+00:00","items":["3.01"],"status":"ready","headline":"aTyr Pharma receives Nasdaq extension to Nov 30, 2026 to cure bid price deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Original bid price deficiency notice received Dec 4, 2025; stock closed below $1.00 for 30 consecutive days.","On June 3, 2026, Nasdaq granted additional 180-day compliance period until November 30, 2026.","Company must maintain closing bid price >= $1.00 for 10 consecutive business days to regain compliance.","aTyr intends to cure deficiency via reverse stock split if necessary during second compliance period.","Failure to regain compliance by Nov 30, 2026 may result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":777839,"accession_number":"0001339970-26-000036","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2026-06-01T20:04:33+00:00","items":["7.01","9.01"],"status":"ready","headline":"aTyr Pharma posts investor presentation highlighting efzofitimod for pulmonary sarcoidosis","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation covers efzofitimod (tRNA synthetase biologic) in pulmonary sarcoidosis and pipeline beyond.","No specific clinical data or financial guidance disclosed in the excerpt provided.","Company presented at investor conferences using these materials; full content not detailed in filing excerpt.","aTyr focuses on tRNA synthetase biology; efzofitimod is their lead candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452717,"accession_number":"0001339970-26-000030","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2026-05-15T12:02:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma reports $68.3M cash; plans Phase 3 for efzofitimod after FDA meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026.","Plans to file IND in June 2026 for a Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease; primary endpoint FVC at week 48.","Phase 3 study to enroll ~372 patients; randomized, double-blind, placebo-controlled, 54 weeks.","On track to complete enrollment in Phase 2 EFZO-CONNECT study for SSc-ILD in first half 2026.","R&D expenses $7.3M and G&A expenses $4.1M for Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12802,"accession_number":"0001339970-26-000027","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2026-05-11T20:03:51+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"aTyr Pharma to launch new Phase 3 study of efzofitimod in pulmonary sarcoidosis after FDA feedback","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Cash, cash equivalents, and investments totaled $68.3M as of March 31, 2026 (unaudited).","FDA Type C meeting endorsed FVC as primary endpoint and KSQ-Lung as key secondary in new Phase 3.","New trial to enroll ~372 patients with restrictive lung disease (FVC ≤80% predicted) on stable corticosteroids.","Dosing changed to 5.0 mg/kg every 3 weeks (from every 4 weeks) with enhanced safety monitoring.","Company plans to submit IND for this Phase 3 study in June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103092,"accession_number":"0001339970-26-000006","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma FY2025 cash $80.9M; Phase 3 sarcoidosis study misses primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 EFZO-FIT missed primary endpoint (corticosteroid dose reduction at week 48), but showed benefit in KSQ-Lung (p=0.0479) and other secondary measures.","Type C FDA meeting scheduled mid-April 2026 to review EFZO-FIT results and determine path forward for efzofitimod in pulmonary sarcoidosis.","Phase 2 EFZO-CONNECT in SSc-ILD on track to complete enrollment in first half 2026; interim data reported Q2 2025.","Year-end 2025 cash position $80.9 million; R&D expenses $60.2 million, G&A $17.6 million for the year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119329,"accession_number":"0001193125-25-309619","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"aTyr Pharma receives Nasdaq bid-price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Dec 4, 2025, Nasdaq notified ATYR that its common stock closed below $1.00 for 30 consecutive business days.","Company has until June 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(a)(2).","If not cured, may be eligible for a second 180-day period by meeting other initial listing standards.","Company may consider a reverse stock split if needed to cure the deficiency.","Failure to regain compliance could lead to delisting and an appeal process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119328,"accession_number":"0001193125-25-269486","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr reports Q3 results; Phase 3 efzofitimod miss but plans FDA meeting","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 EFZO-FIT missed primary endpoint of corticosteroid dose reduction at week 48; 5.0 mg/kg showed benefit on multiple quality-of-life measures.","Company plans FDA meeting in Q1 2026 to discuss path forward for efzofitimod in pulmonary sarcoidosis.","Phase 2 EFZO-CONNECT enrollment in SSc-ILD expected to complete H1 2026; interim data reported Q2 2025.","Cash, equivalents, restricted cash and investments $92.9M as of Sep 30, 2025.","R&D expenses $22.1M, G&A $4.8M for Q3 2025."],"consensus_eps_estimate":-0.1873,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":190000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135899,"accession_number":"0001193125-25-202865","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"aTyr Pharma Phase 3 EFZO-FIT study misses primary endpoint in pulmonary sarcoidosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: change from baseline in mean daily OCS dose at week 48; p=0.3313 (2.79 mg efzofitimod vs 3.52 mg placebo).","Nominal KSQ-Lung score improvement for 5.0 mg/kg vs placebo (p=0.0479); steroid withdrawal with KSQ-Lung improvement p=0.0199.","FVC maintained; safety consistent with prior trials; company plans to engage FDA on path forward.","Study enrolled 268 patients; hierarchical testing stopped after primary miss; all subsequent p-values nominal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135897,"accession_number":"0001339970-25-000016","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K/A","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01","2.06"],"status":"ready","headline":"aTyr Pharma Phase 3 EFZO-FIT topline due mid-Sept; Q2 cash $83.2M, raised $30.7M ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed last patient visit in Phase 3 EFZO-FIT study for pulmonary sarcoidosis; topline results expected mid-September 2025.","Interim Phase 2 data in SSc-ILD showed stable/improved mRSS in diffuse patients; no treatment-related serious adverse events.","ATYR0101 advanced to IND candidate for pulmonary fibrosis; IND filing planned in H2 2026.","Cash, equivalents and investments $83.2M at June 30, 2025; raised ~$30.7M in ATM offering after quarter-end.","R&D expenses $15.4M, G&A $4.9M for Q2 2025; cash runway sufficient for one year after Phase 3 readout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135898,"accession_number":"0001339970-25-000007","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr completes Phase 3 EFZO-FIT last patient visit; topline data mid-September 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient visit completed in Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis; topline data expected mid-September 2025.","Cash, equivalents and investments were $83.2M at June 30, 2025; raised ~$30.7M from ATM offering post-quarter.","R&D expenses $15.4M, G&A $4.9M for Q2 2025.","Interim Phase 2 EFZO-CONNECT data in SSc-ILD showed stable/improved mRSS in efzofitimod-treated patients (n=8).","Advanced ATYR0101 to IND candidate for pulmonary fibrosis; IND filing expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152885,"accession_number":"0000950170-25-065611","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma reports Q1 cash of $78.8M; Phase 3 sarcoidosis data on track for Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, restricted cash and investments at $78.8M as of March 31, 2025; cash runway sufficient for one year after Phase 3 readout.","Phase 3 EFZO-FIT top-line data (efzofitimod in pulmonary sarcoidosis) expected in Q3 2025; 268 patients enrolled at 85 sites.","Phase 2 EFZO-CONNECT (SSc-ILD) interim data on skin assessments expected in Q2 2025; up to 25 patients.","Appointed Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise; 25+ years industry experience.","R&D expenses $11.8M and G&A $4.0M in Q1 2025; preclinical ATYR2810 data presented at AACR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152884,"accession_number":"0000950170-25-064413","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"aTyr Pharma shareholders approve 5M share increase to equity plan; elect two directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2015 Stock Plan, increasing share reserve by 5,000,000 to 15,719,300 shares.","Incentive stock option term extended to February 26, 2035.","Class I directors Paul Schimmel and Sara L. Zaknoen elected with 56.6M and 49.0M votes for, respectively.","Ratification of Ernst & Young as auditor for FY2025 approved (68.9M for, 175K against).","Advisory vote on named executive officer compensation approved (55.2M for, 1.35M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171696,"accession_number":"0000950170-25-038703","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma reports year-end 2024 cash of $75.1M; Phase 3 topline data due Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $75.1M as of Dec 31, 2024; raised ~$18.8M via ATM after quarter-end.","Phase 3 EFZO-FIT enrollment complete (268 patients); topline pulmonary sarcoidosis data expected Q3 2025.","Fourth positive DSMB review; FDA meeting finalized SAP on steroid reduction endpoint.","Phase 2 EFZO-CONNECT interim data for scleroderma-ILD expected Q2 2025.","R&D expenses $54.4M, G&A $13.8M for FY2024; cash runway extends one year past Phase 3 readout."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188690,"accession_number":"0000950170-24-139633","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"aTyr Pharma expands at-the-market equity facility with Jefferies after exhausting prior $65M capacity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 23, 2024, amended Open Market Sale Agreement with Jefferies to allow additional common stock sales.","Prior aggregate offering amount of $65M under the Sales Agreement was fully sold as of the amendment date.","New shares may be sold at the market; amount governed by prospectus supplement filed December 23, 2024.","Original terms and conditions of the Sales Agreement remain unchanged; Jefferies will use commercially reasonable efforts.","Issuance will be made under effective registration statement on Form S-3 (File No. 333-275455)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188689,"accession_number":"0000950170-24-135766","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"aTyr Pharma appoints Eric Benevich to board; amends director compensation policy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Benevich appointed as Class II director effective Dec 10, 2024, term through 2026 annual meeting.","Granted option to purchase 100,000 shares at Dec 10 closing price, vesting equally over 36 months.","Amended Non-Employee Director Compensation Policy: annual retainer $40,000; committee fees $5,000–$20,000.","Initial equity grant for new non-employee directors set at 100,000 options; annual grant 50,000 options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188688,"accession_number":"0000950170-24-123256","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma completes Phase 3 enrollment in pulmonary sarcoidosis; topline data Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 EFZO-FIT enrolled 268 patients (target exceeded) at 85 centers in 9 countries; topline data expected Q3 2025.","Cash, equivalents, and investments $68.9M at Sep 30, 2024; raised ~$19.4M in ATM offering post-quarter.","R&D expenses $14.8M and G&A $3.3M in Q3 2024; cash runway projected through BLA filing for efzofitimod.","Publication in European Respiratory Journal showed significant reduction in corticosteroid relapse with efzofitimod.","Phase 2 EFZO-CONNECT in SSc-ILD enrolling; interim data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":235000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205155,"accession_number":"0000950170-24-096139","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma completes Phase 3 sarcoidosis trial enrollment; Q2 cash $81.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolled 268 patients; topline data expected Q3 2025.","Cash, equivalents, restricted cash and investments totaled $81.4M as of June 30, 2024.","R&D expenses $14.0M, G&A $3.3M for Q2 2024.","Phase 2 EFZO-CONNECT for SSc-ILD enrolling; interim data expected Q2 2025.","Appointed Jayant Aphale VP Technical Operations; research agreement with Stanford for anti-NRP2 in GBM."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":235000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205154,"accession_number":"0000950170-24-085058","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"aTyr Pharma completes Phase 3 enrollment for efzofitimod; topline data Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled 268 patients in EFZO-FIT study, exceeding target enrollment.","Trial conducted at 85 centers across 9 countries.","Topline data expected in Q3 2025.","Phase 3 study is pivotal, randomized, double-blind, placebo-controlled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222036,"accession_number":"0000950170-24-065899","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","5.07","5.05","8.01","9.01"],"status":"ready","headline":"aTyr Pharma shareholders approve stock plan increase and report Phase 3 trial enrollment progress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2015 Stock Plan, increasing shares reserved by 3,000,000 to 10,713,670.","Svetlana Lucas and Sanjay Shukla elected as Class III directors with majority votes.","Ratification of Ernst & Young as independent auditor for FY2024 (54.5M for, 327K against).","Advisory approval of executive compensation (42.5M for, 398K against).","Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis anticipates completing enrollment in Q2 2024; final patient dosing may occur in July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222035,"accession_number":"0000950170-24-052058","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma Q1 2024 update: Phase 3 EFZO-FIT completes enrollment expected in Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents, restricted cash and investments totaled $87.7 million as of March 31, 2024.","Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrollment completion expected in Q2 2024.","Phase 2 EFZO-CONNECT study in systemic sclerosis-associated ILD enrolling at multiple U.S. sites.","R&D expenses of $13.4 million and G&A expenses of $3.5 million for Q1 2024.","Collaboration revenue of $0.2 million from Kyorin agreement for drug product material sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241561,"accession_number":"0000950170-24-031441","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma reports FY2023 cash $101.7M; Phase 3 sarcoidosis study enrollment to complete Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents, restricted cash, investments at Dec 31, 2023: $101.7M; cash runway through BLA filing.","Phase 3 EFZO-FIT study in pulmonary sarcoidosis enrollment expected to complete Q2 2024; DSMB allowed unmodified continuation.","Launched Individual Patient Expanded Access Program for patients completing EFZO-FIT study.","Phase 2 EFZO-CONNECT study in SSc-ILD enrolling (proof-of-concept, up to 25 patients); multiple U.S. sites open.","R&D expenses $42.3M, G&A $13.0M for year 2023; no product revenue as clinical-stage biotech."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259011,"accession_number":"0000950170-23-062020","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma reports Q3 2023 cash of $105.6M; Phase 3 sarcoidosis study enrollment to complete early Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments totaled $105.6M as of September 30, 2023.","Phase 3 EFZO-FIT study in pulmonary sarcoidosis expects enrollment completion early Q2 2024; positive DSMB safety review.","Phase 2 EFZO-CONNECT study in systemic sclerosis-ILD dosed first patient.","R&D expenses were $10.3M, G&A $2.6M, collaboration revenue $0.4M from Kyorin agreement.","Updated cash runway guidance: sufficient through BLA filing for efzofitimod in sarcoidosis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":353000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276302,"accession_number":"0000950170-23-049802","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"aTyr Pharma initiates Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EFZO-CONNECT is a randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study in systemic sclerosis-associated ILD.","Study enrolls 25 patients across multiple US centers; 28-week treatment with monthly IV doses of efzofitimod (270 mg or 450 mg) or placebo.","Primary objective: evaluate efficacy of efzofitimod on pulmonary, cutaneous, and systemic manifestations in SSc-ILD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276301,"accession_number":"0000950170-23-047360","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"aTyr Pharma reports positive Phase 1b/2a post-hoc data for efzofitimod in sarcoidosis","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Therapeutic doses (3.0 & 5.0 mg/kg) reduced steroid relapse rate to 7.7% vs 54.4% (p=0.017).","FVC rate of change significantly improved for therapeutic vs placebo/subtherapeutic group (p=0.035).","52.9% of therapeutic group achieved ≥12 KSQ-L improvement (3x MCID) vs 15.0% (p=0.032).","64.7% of therapeutic group met composite responder endpoint vs 20.0% (p=0.008)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276300,"accession_number":"0000950170-23-040581","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma Q2 2023: cash $112M, R&D $9.8M; Phase 3 EFZO-FIT enrolling globally","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $112.0M as of June 30, 2023; company expects cash runway into 2026.","R&D expenses $9.8M, G&A $3.7M in Q2 2023.","Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling up to 264 subjects globally.","Phase 2 EFZO-CONNECT study in SSc-ILD expected to start Q3 2023, enrolling 25 patients.","Received European Commission orphan drug designation for efzofitimod in systemic sclerosis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293983,"accession_number":"0000950170-23-023257","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02","5.07","5.03","5.05","9.01"],"status":"ready","headline":"aTyr Pharma stockholders approve doubling of authorized shares and equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 85M to 170M via Charter Amendment filed May 18, 2023.","2015 Stock Plan share reserve increased by 4M shares to 7,711,868 (post-reverse split).","Two Class II directors elected: Timothy P. Coughlin and Jane A. Gross, Ph.D., until 2026.","Ernst & Young ratified as independent auditor for FY 2023 with 44.5M votes for.","Advisory say-on-pay compensation approved with 37.2M for, 1.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":293982,"accession_number":"0000950170-23-019633","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma reports Q1 2023 cash of $117.6M; Phase 3 sarcoidosis trial enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments of $117.6M as of March 31, 2023; $48.1M net from February stock offering.","Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling in U.S., Europe and Japan; up to 264 subjects.","Phase 2 proof-of-concept study in SSc-ILD expected to initiate Q3 2023; 25 patients, multiple U.S. centers.","R&D expenses $9.4M and G&A expenses $3.4M for Q1 2023; cash runway projected into 2026.","Multiple efzofitimod presentations planned at ATS 2023 International Conference May 19-24."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314594,"accession_number":"0000950170-23-007341","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"aTyr Pharma holds less than 2% of cash at failed SVB; exposure limited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of March 10, 2023, aTyr holds less than 2% of cash equivalents and investments at SVB.","Company acknowledges SVB closure and FDIC receivership in SEC filing.","Remaining >98% of cash is held at other institutions, minimizing direct risk.","No material financial or operational impact anticipated from SVB failure.","Disclosure made under Regulation FD on March 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314593,"accession_number":"0000950170-23-007002","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma FY2022 cash $69.3M; Phase 3 EFZO-FIT enrolling globally; $52M Feb offering extends runway to 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & investments $69.3M at Dec 31, 2022; Feb 2023 offering raised ~$52M gross plus $10M milestone from Kyorin; runway into 2026.","R&D expense $42.8M, G&A $14.0M for full year 2022; pre-revenue biotech with no product sales.","Phase 3 EFZO-FIT (sarcoidosis) enrolling in U.S., Europe, Japan; Kyorin dosed first patient in Japan triggering $10M milestone.","FDA cleared IND for Phase 2 proof-of-concept SSc-ILD study; EU orphan designation for efzofitimod in sarcoidosis.","LTBP1 identified as target of DARS domain; European patent allowance for efzofitimod + pirfenidone combo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314592,"accession_number":"0000950170-23-002384","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"aTyr Pharma launches $50M public offering of 22.2M shares at $2.25; plans Phase 2 SSc-ILD study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$50M from 22,225,000 shares at $2.25; underwriters have 30-day option for 3,333,750 additional shares.","FDA cleared IND for efzofitimod in SSc-ILD; Phase 2 proof-of-concept study planned for 2023.","Phase 2 study: 28-week, randomized, double-blind, placebo-controlled, 2:2:1 dosing 270 mg, 450 mg efzofitimod or placebo; 25 patients.","Orphan drug designations: FDA: sarcoidosis (Jan 2022) and systemic sclerosis (Apr 2022); EU: sarcoidosis (Jan 2023).","Risk factor supplement: no guarantee of orphan drug exclusivity for future indications or jurisdictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314591,"accession_number":"0000950170-23-001836","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"aTyr Pharma's partner Kyorin doses first patient in Phase 3 EFZO-FIT study; receives $10M milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kyorin dosed first patient in Japan in global pivotal Phase 3 EFZO-FIT trial of efzofitimod for pulmonary sarcoidosis.","Milestone payment of $10M triggered under Kyorin agreement; total upfront and milestones to date $20M.","aTyr eligible for up to $155M additional development, regulatory, and sales milestones plus royalties on Japan net sales.","Kyorin holds exclusive rights to develop and commercialize efzofitimod for all interstitial lung diseases in Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333014,"accession_number":"0000950170-22-024480","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma reports Q3 2022 cash $79.6M; Phase 3 sarcoidosis study initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Ended Q3 2022 with $79.6M in cash, restricted cash, cash equivalents and investments.","First patient dosed in EFZO-FIT Phase 3 study of efzofitimod for pulmonary sarcoidosis; targets 264 subjects.","Will not initiate Phase 1 for ATYR2810 this year; pursuing external non-dilutive funding.","FDA granted Fast Track designation for efzofitimod in systemic sclerosis-associated ILD.","Q3 R&D expenses $9.9M, G&A $3.6M; 29.0M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350462,"accession_number":"0000950170-22-017380","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma Q2 2022 cash $89.3M; initiates Phase 3 sarcoidosis study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, restricted cash, cash equivalents and investments $89.3M as of June 30, 2022.","R&D expenses $9.1M, G&A expenses $3.4M for Q2 2022; no revenue reported.","First sites initiated in global Phase 3 EFZO-FIT study for pulmonary sarcoidosis.","FDA Fast Track designation granted for efzofitimod in pulmonary sarcoidosis.","Company on track to enroll first patient in Q3 2022; 28.1M shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350461,"accession_number":"0000950170-22-016670","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"aTyr Pharma gets FDA Fast Track for efzofitimod in pulmonary sarcoidosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track designation on August 9, 2022 for lead candidate efzofitimod.","Fast Track aims to expedite development and review; may allow rolling submission.","Pulmonary sarcoidosis is a major interstitial lung disease with no approved therapies.","Efzofitimod is a novel immunomodulator targeting neuropilin-2; Phase 3 trial ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367624,"accession_number":"0001564590-22-020476","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":[],"status":"ready","headline":"aTyr Pharma launches Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis, citing positive Phase 1b/2a data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 EFZO-FIT will enroll 264 patients; primary endpoint is steroid reduction; secondary endpoints include lung function and symptoms.","Phase 1b/2a data showed dose-dependent improvements; 5.0 mg/kg group had three patients completely taper off steroids.","Efzofitimod demonstrated control of inflammatory biomarkers (IFN-γ, IL-6, IP-10, MCP-1, TNFa) over 24 weeks.","Two higher doses (3.0 and 5.0 mg/kg) improved lung function measures (FVC, DLCO) vs placebo.","Trial expected to initiate Q3 2022; Phase 1b/2a results presented at ATS 2022 conference May 17."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367623,"accession_number":"0001564590-22-020382","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":[],"status":"ready","headline":"aTyr Pharma enters 124-month lease for ~23,696 SF office/lab space in San Diego; $5.75/sqft base rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term of 124 months starting April 1, 2023, with option to extend for 5 years.","Base rent $5.75/sqft/month first year, escalating ~3% annually.","Tenant improvement allowance of $5,450,080; optional additional $592,400 at 8% amortization.","Security deposit of $732,680 in form of letter of credit.","Premises at 10240 Sorrento Valley Road for office, lab, R&D uses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367622,"accession_number":"0001564590-22-018868","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"aTyr Pharma Q1 2022 cash $98.7M; on track for registrational study in pulmonary sarcoidosis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $98.7M at March 31, 2022; R&D expenses $8.9M, G&A $3.5M.","Phase 1b/2a efzofitimod data to be presented at ATS 2022; registrational study planned for Q3 2022.","FDA orphan drug designation for efzofitimod in systemic sclerosis; exploring expansion into other ILDs.","ATYR2810 IND candidate; Phase 1 study in cancer expected in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367621,"accession_number":"0001564590-22-016548","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"aTyr Pharma stockholders approve doubling authorized shares to 85M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized common shares from 42.5M to 85,000,000.","Amendment to 2015 Stock Plan approved, increasing reserved shares by 2,000,000.","Amendment to 2015 ESPP approved, increasing reserved shares by 750,000 and per-employee limit to 2,500.","All three Class I director nominees elected (John Clarke, Paul Schimmel, Sara Zaknoen).","Ratification of Ernst & Young as auditor and advisory approval of executive compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367620,"accession_number":"0001564590-22-015295","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-04-22T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"aTyr Pharma enters into $65M at-the-market offering agreement with Jefferies, terminates prior JonesTrading ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["aTyr Pharma entered into Open Market Sale Agreement with Jefferies LLC to sell up to $65M of common stock at market prices on Nasdaq.","The agreement includes a 3.0% commission to Jefferies on gross proceeds from each sale of shares.","Company terminated the prior Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC dated March 23, 2021.","Prior agreement allowed up to $25M in common stock sales through JonesTrading as sales agent.","Shares will be sold under existing shelf registration statement (File No. 333-250095) effective November 23, 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367618,"accession_number":"0001564590-22-014489","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K/A","filed_at":"2022-04-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA grants orphan drug designation to aTyr Pharma's efzofitimod for systemic sclerosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.","Orphan designation may provide 7-year market exclusivity, tax credits, and waiver of FDA fees.","Efzofitimod is aTyr's lead therapeutic candidate; this designation supports its development program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367619,"accession_number":"0001564590-22-014285","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"aTyr Pharma gets FDA orphan drug designation for efzofitimod in systemic sclerosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.","Efzofitimod is aTyr's lead therapeutic candidate; orphan status provides development incentives and market exclusivity potential.","Systemic sclerosis is a rare autoimmune disease; designation underscores unmet medical need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":386977,"accession_number":"0001564590-22-010086","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"aTyr Pharma posts $107.9M cash; FDA path for efzofitimod registrational trial in Q3 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments of $107.9M as of Dec 31, 2021.","FDA End-of-Phase 2 meeting provides development pathway; registrational trial for efzofitimod in pulmonary sarcoidosis planned to start Q3 2022.","Orphan drug designation granted for efzofitimod in sarcoidosis.","ATYR2810 Phase 1 study expected to initiate in H2 2022.","R&D expenses $23.3M in 2021, expected to increase in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":404894,"accession_number":"0001564590-21-056179","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma reports positive Phase 1b/2a results for ATYR1923; Q3 cash $116.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive proof-of-concept data for ATYR1923 in pulmonary sarcoidosis; registrational trial expected in 2022.","Cash, cash equivalents and investments $116.4M at Sept 30, 2021, after $80.6M net from stock offering.","R&D expenses $5.1M and G&A $2.6M for Q3 2021; 27.8M shares outstanding.","Appointed Robert W. Ashworth, PhD, as VP of Regulatory Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423914,"accession_number":"0001564590-21-048145","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2021-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"aTyr Pharma prices $75M public offering of 9.375M shares at $8.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds expected ~$75M from 9,375,000 shares at $8.00/share.","Underwriters granted 30-day option to purchase up to 1,406,250 additional shares.","Offering expected to close on September 20, 2021, subject to customary conditions.","Joint book-running managers: Piper Sandler and RBC Capital Markets; Laidlaw & Co. as lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423913,"accession_number":"0001564590-21-047679","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"aTyr Pharma Announces Positive Phase 1b/2a Results for ATYR1923 in Pulmonary Sarcoidosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATYR1923 safe and well-tolerated with no drug-related serious adverse events in 37-patient pulmonary sarcoidosis trial.","5.0 mg/kg group achieved 58% steroid reduction from baseline and 33% of patients tapered completely off steroids.","Absolute improvement in forced vital capacity (FVC) of 3.3% at week 24 in 5.0 mg/kg group vs placebo.","Clinically meaningful improvements in dyspnea, cough, fatigue and King's Sarcoidosis scores in 5.0 mg/kg group.","Company plans FDA end-of-Phase 2 meeting and expects to initiate registrational trial in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":423912,"accession_number":"0001564590-21-043086","cik":1339970,"company_name":"aTYR PHARMA INC","ticker":"ATYR","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"aTyr Pharma Q2 cash $44.1M; sarcoidosis data readout expected mid-September","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $44.1M as of June 30, 2021; R&D expense $7.7M, G&A $2.8M.","Last patient visit completed in Phase 1b/2a study of ATYR1923 in pulmonary sarcoidosis; data due mid-September 2021.","Kyorin completed Phase 1 study of ATYR1923 in 32 Japanese volunteers; safe, well-tolerated, PK consistent.","Appointed Sara Zaknoen, M.D. to board; received US patent for ATYR1923 lung inflammation methods.","Shares outstanding 16.9M as of Aug 9, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":46152702.95043915,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}